Gene Panel Market, Outlook, Revenue Models 2028
The "Global Retinal Biologics Market" is predicted to reach at a high CAGR of 19.6% during the forecast period (2021-2028)
(EMAILWIRE.COM, October 05, 2021 )
Market Overview
A gene panel is a test that helps analyze multiple genes at the same time for cancer-associated mutations. BRCA1 and BRCA2 are two genes responsible for the production of proteins that help in suppressing tumors. These proteins help in repairing damaged DNA and prevent the growth of tumor cells.
View full report: https://bit.ly/3DcBKBP
Market Dynamics
The gene panel market growth is driven by the rising prevalence of chronic diseases and increasing technological advancement in diagnostics services and methods, growing company initiatives, and rising adoption of gene panels owing to the benefits they offer.
The rising prevalence of the chronic disease is expected to drive growth in the forecast period.
The gene panels are used in diagnostics and treatments like Cancer Risk Assessment, Syndrome-Specific Diagnostics, Disease Penetration, and many other applications. Based on the data published by the World Health organization, in 2020, the chronic disease contribution is expected to rise to 73% of all deaths and 60% of the global burden of disease.
Moreover, 79% attributed to these diseases occur in developing countries. Four of the most prominent chronic diseases are cardiovascular diseases (CVD), cancer, chronic obstructive pulmonary disease, and diabetes. This will ultimately upsurge the demand for gene panels over the forecasted period.
The rising adoption of gene panels owing to the benefits they offer is expected to drive the growth in the forecast period.
A multi-gene panel test provides better diagnostic yield than a limited BRCA1/2 genetic test for patients at risk for hereditary breast cancer. This single reliable test provides more information for women suspected to have hereditary cancer predisposition, particularly for breast and ovarian cancers.
Besides this, in a retrospective comparison of multiple genetic tests, there was no difference between the multi-gene panel test and the limited BRCA1/2 test in the detection of potentially harmful BRCA mutations.
Segmentation
By Product & Service
• Test Kits
• Testing Services
By Technique
• Hybridization-based Approach
• Amplicon-based Approach
By Design
• Predesigned Gene Panel
• Customized Gene Panel
By Application
• Cancer Risk Assessment
• Diagnosis of Congenital Diseases
By End-user
• Hospital and Diagnostic Laboratories
• Research and Academic Institutes
Download free sample: https://bit.ly/3l75ABw
Geographical Analysis
North America region holds the largest market share of the global gene panel market.
North America accounted for the largest market share. Consumer demand for safe and effective genetic tests is fueling the growth of the gene panel market. Nonetheless, the growing demand for personalized medicine and the growing Application of genetic testing in oncology are fueling the growth of the North American gene panel market.
In addition, growth in the aging population, the subsequent increase in chronic diseases, advancements of technology in the genetic testing space, and rising cancer cases are few primary factors that are propelling the growth of the market. For instance, QIAGEN and INOVIO Expand Collaboration to Develop Next-Generation Sequencing (NGS) Companion Diagnostic for INOVIOs VGX-3100 for Advanced Cervical Dysplasia.
Competitive Landscape
The global gene panel market is highly competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Illumina, Inc, Thermo Fisher Scientific, Agilent Technologies, QIAGEN, BGI (China), Eurofins Scientific, Novogene Corporation (China), F. Hoffmann-La Roche AG, Integrated DNA Technologies, Genewiz, Inc.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, The Ethiopian Biotechnology Institute (EBTi) and BGI Health Ethiopia PLC signed a memorandum of understanding (MoU) in the HPV Genotyping Pilot Project and technological relations.
Related Topic's
Gene Expression Analysis Market, Generic Drugs Market, Gene Therapy Market, Gene Therapies, Genetic Testing Market
Market Overview
A gene panel is a test that helps analyze multiple genes at the same time for cancer-associated mutations. BRCA1 and BRCA2 are two genes responsible for the production of proteins that help in suppressing tumors. These proteins help in repairing damaged DNA and prevent the growth of tumor cells.
View full report: https://bit.ly/3DcBKBP
Market Dynamics
The gene panel market growth is driven by the rising prevalence of chronic diseases and increasing technological advancement in diagnostics services and methods, growing company initiatives, and rising adoption of gene panels owing to the benefits they offer.
The rising prevalence of the chronic disease is expected to drive growth in the forecast period.
The gene panels are used in diagnostics and treatments like Cancer Risk Assessment, Syndrome-Specific Diagnostics, Disease Penetration, and many other applications. Based on the data published by the World Health organization, in 2020, the chronic disease contribution is expected to rise to 73% of all deaths and 60% of the global burden of disease.
Moreover, 79% attributed to these diseases occur in developing countries. Four of the most prominent chronic diseases are cardiovascular diseases (CVD), cancer, chronic obstructive pulmonary disease, and diabetes. This will ultimately upsurge the demand for gene panels over the forecasted period.
The rising adoption of gene panels owing to the benefits they offer is expected to drive the growth in the forecast period.
A multi-gene panel test provides better diagnostic yield than a limited BRCA1/2 genetic test for patients at risk for hereditary breast cancer. This single reliable test provides more information for women suspected to have hereditary cancer predisposition, particularly for breast and ovarian cancers.
Besides this, in a retrospective comparison of multiple genetic tests, there was no difference between the multi-gene panel test and the limited BRCA1/2 test in the detection of potentially harmful BRCA mutations.
Segmentation
By Product & Service
• Test Kits
• Testing Services
By Technique
• Hybridization-based Approach
• Amplicon-based Approach
By Design
• Predesigned Gene Panel
• Customized Gene Panel
By Application
• Cancer Risk Assessment
• Diagnosis of Congenital Diseases
By End-user
• Hospital and Diagnostic Laboratories
• Research and Academic Institutes
Download free sample: https://bit.ly/3l75ABw
Geographical Analysis
North America region holds the largest market share of the global gene panel market.
North America accounted for the largest market share. Consumer demand for safe and effective genetic tests is fueling the growth of the gene panel market. Nonetheless, the growing demand for personalized medicine and the growing Application of genetic testing in oncology are fueling the growth of the North American gene panel market.
In addition, growth in the aging population, the subsequent increase in chronic diseases, advancements of technology in the genetic testing space, and rising cancer cases are few primary factors that are propelling the growth of the market. For instance, QIAGEN and INOVIO Expand Collaboration to Develop Next-Generation Sequencing (NGS) Companion Diagnostic for INOVIOs VGX-3100 for Advanced Cervical Dysplasia.
Competitive Landscape
The global gene panel market is highly competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Illumina, Inc, Thermo Fisher Scientific, Agilent Technologies, QIAGEN, BGI (China), Eurofins Scientific, Novogene Corporation (China), F. Hoffmann-La Roche AG, Integrated DNA Technologies, Genewiz, Inc.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, The Ethiopian Biotechnology Institute (EBTi) and BGI Health Ethiopia PLC signed a memorandum of understanding (MoU) in the HPV Genotyping Pilot Project and technological relations.
Related Topic's
Gene Expression Analysis Market, Generic Drugs Market, Gene Therapy Market, Gene Therapies, Genetic Testing Market
Contact Information:
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results